Mesa Biotech, Inc.

Mesa Biotech, Inc. is a molecular diagnostic company based in San Diego, specializing in PCR-based rapid point-of-care testing for infectious diseases. Founded in 2009 by Drs. Hong Cai and Bruce Cary, the company has grown to around 500 employees and reported revenues of approximately $45 million in 2020. Its flagship product, the Accula System, provides accurate diagnostic results in just 30 minutes, making it suitable for use in physician offices and pharmacies. The Accula System offers tests for various infectious diseases, including SARS-CoV-2 (COVID-19), Influenza A and B, Respiratory Syncytial Virus (RSV), and Group A Streptococcus (Strep A). These tests have received regulatory approvals, allowing them to be used in low-complexity settings. Mesa Biotech emphasizes a simple design and scalable manufacturing, enabling rapid responses to healthcare needs, particularly during the COVID-19 pandemic. In 2021, the company was acquired by Thermo Fisher Scientific, enhancing its ability to expand its global reach and product offerings in molecular diagnostics.

• Employees 27
• Founded 2009
• Annual Revenue $45000000
• Total Funding $43196562